BioSpace News Archive

Deals

Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”) and Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) today announced the closing of the initial public offering (“IPO”) of Bausch + Lomb.

May 10, 2022
·
5 min read
Genetown

GreenLight’s honeybee-saving RNA solution named finalist in World Changing Ideas Award

An RNA-based solution by GreenLight Biosciences designed to protect honeybees from the Varroa destructor mite was named a finalist by Fast Company for its 2022 World Changing Ideas Awards.

May 10, 2022
·
2 min read
Business

Codex DNA Reports First Quarter 2022 Financial Results

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, reported financial results for the first quarter ended March 31, 2022.

May 10, 2022
·
6 min read
Business

Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Journey Medical Corporation announced financial results and recent corporate highlights for the first quarter ended March 31, 2022.

May 10, 2022
·
14 min read
Business

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.

May 10, 2022
·
6 min read
Business

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2022.

May 10, 2022
·
8 min read
Pharm Country

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

Amicus Therapeutics announced that the U.S. Food and Drug Administration has extended the review period by 90 days for the Biologics License Application for cipaglucosidase alfa and the New Drug Application for miglustat, the two components of AT-GAA.

May 10, 2022
·
5 min read
Drug Development

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma

Arcellx, Inc. announced that the first patient has been dosed in its open-label, multicenter ACLX-001 Phase 1 clinical trial to evaluate the company’s novel ARC-SparX program in patients with relapsed or refractory multiple myeloma.

May 10, 2022
·
6 min read
Business

Halozyme Reports First Quarter 2022 Results

Halozyme Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on its recent corporate activities and outlook.

May 10, 2022
·
17 min read
Business

Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.

May 10, 2022
·
8 min read